Is tirzepatide legal in New Zealand?

The short answer

Tirzepatide occupies two separate regulatory categories in New Zealand, and keeping them apart is the whole point of this article. As a medicine, tirzepatide is registered on the New Zealand Register of Therapeutic Goods under the brand name Mounjaro, and it sits in the Poisons Standard as a Schedule 4 Prescription Only Medicine. In that form it is lawful to supply when a doctor has prescribed it and a pharmacy has dispensed it.

Separately, there is research-grade tirzepatide that is supplied for laboratory use only. This material is not a registered medicine, is not for human use, and should not be confused with the pharmacy product. Synergy Bio supplies research-use-only materials in this second category, not medicines.

What tirzepatide is

Tirzepatide is a synthetic peptide. In pharmacology it is described as a dual agonist, meaning it acts at two receptors: the glucose-dependent insulinotropic polypeptide receptor, usually abbreviated GIP, and the glucagon-like peptide-1 receptor, usually abbreviated GLP-1. This dual GIP and GLP-1 receptor activity is what distinguishes tirzepatide from single-target GLP-1 molecules such as semaglutide.

Because it is a defined peptide with documented receptor activity, tirzepatide is also a subject of scientific study, which is why research-grade reference material exists alongside the registered medicine. The scope of this article is regulatory status in New Zealand, not any physiological or therapeutic outcome.

ARTG registration and the Mounjaro brand

The New Zealand Register of Therapeutic Goods, or ARTG, is the national list of therapeutic goods that may be lawfully supplied as medicines in New Zealand. The Therapeutic Goods Administration, the TGA, maintains it. A product being on the ARTG means the TGA has assessed it and entered it onto the register for supply as a medicine.

Tirzepatide is registered on the ARTG under the brand name Mounjaro, marketed by Eli Lilly. The TGA records show the assessment concluded in late 2022 and the product entered the register at that time. There are multiple ARTG entries covering different pen presentations of the same active ingredient.

A naming note that often causes confusion: in the United States, tirzepatide is marketed under two brands, Mounjaro and Zepbound, for different registered uses. In New Zealand the brand name associated with tirzepatide is Mounjaro. If you see the name Zepbound it generally refers to the United States market rather than the New Zealand register.

Schedule 4: what prescription only means

The Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons, places substances into schedules that determine how they may be accessed. Tirzepatide as a medicine is classified Schedule 4, which is Prescription Only Medicine.

In practical terms, Schedule 4 means the medicine form of tirzepatide is lawful to supply only on a valid prescription written by an authorised prescriber, and it is dispensed through a pharmacy. It is not an over-the-counter product, and it is not something a member of the public can lawfully buy as a medicine without a prescription.

The medicine pathway in brief

• A substance is entered on the ARTG as a medicine, in this case Mounjaro.
• The Poisons Standard assigns a schedule, in this case Schedule 4.
• Access is through a prescriber and a pharmacy, not general retail.

Registered medicine versus research-grade material

This is the nuance that sets tirzepatide apart from some other peptides often asked about, such as BPC-157 or retatrutide, which are not registered as medicines in New Zealand. Tirzepatide is different because the molecule does have an approved, registered medicine form. That does not mean every form of the molecule is a medicine.

Research-grade tirzepatide is supplied as a laboratory reference material for research use only. It is not entered on the ARTG as a medicine, it is not assessed for human administration, and it is not dispensed through a pharmacy. It exists for in-vitro and laboratory contexts, not for people.

The honest framing is therefore this: tirzepatide is legal in New Zealand as a prescription medicine, Mounjaro, when prescribed and dispensed appropriately. Research-grade tirzepatide supplied for laboratory use is a separate, non-registered category that is not a medicine and is not for human use. Synergy Bio operates only in the research-use-only category.

Sport and anti-doping status

People sometimes ask whether tirzepatide is relevant to anti-doping rules. Based on current public information, GLP-1 and dual GIP and GLP-1 receptor agonists, including tirzepatide and semaglutide, are not on the World Anti-Doping Agency Prohibited List as at 2026. They have, however, been placed on WADA's Monitoring Programme, which lets the agency track patterns of use without that status itself being a sanction.

This differs from some growth-hormone-related peptides, which do appear on the Prohibited List. The point here is purely factual and neutral: monitoring status is not a ban, and athletes bound by Sport Integrity New Zealand rules should always confirm the current list directly rather than rely on a general summary.

Supply, compliance, and common pitfalls

Because the same molecule exists both as a registered medicine and as a research material, the most common error is treating one as if it were the other. Research-grade tirzepatide is not a substitute for a pharmacy-dispensed medicine, and it is not supplied for that purpose.

Points worth keeping straight

• The medicine form is Mounjaro, Schedule 4, prescription only, dispensed by a pharmacy.
• Research-grade tirzepatide is not registered on the ARTG and is for laboratory use only.
• Research materials are not medicines and carry no therapeutic, efficacy, or outcome claims.
• Regulatory status and scheduling can change, so always verify the current position.

Synergy Bio supplies tirzepatide strictly as a research-use-only laboratory material. We make no therapeutic claims, provide no human use guidance, and do not supply it as a medicine. If you are seeking the medicine, that is a matter for a qualified prescriber and a pharmacy.

Summary

Is tirzepatide legal in New Zealand? As a medicine it is, in the form of Mounjaro, which is ARTG registered and classified Schedule 4 Prescription Only Medicine, so it is lawful when prescribed and dispensed through the usual pharmacy pathway. Research-grade tirzepatide is a distinct, non-registered category supplied for laboratory use only and is not a medicine.

Understanding which category you are dealing with is the key to understanding the law around it. This article is general information only and is not legal or medical advice.

Frequently asked questions